{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:37:12Z","timestamp":1783445832955,"version":"3.54.6"},"reference-count":53,"publisher":"Georg Thieme Verlag KG","issue":"12","funder":[{"name":"Clinician Scientist program RISE funded by the Else-Kr\u00f6ner-Fresenius-Stiftung & the Eva-Luise\u2013und-Horst-K\u00f6hler Stiftung"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Endocrinol Diabetes"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Endogenous Cushing\u2019s syndrome (CS) is a rare disease characterized by a\n                    glucocorticoid excess. If inadequately treated, hypercortisolism can lead to\n                    increased morbidity and mortality. Surgical removal of the underlying tumor is\n                    the first-line treatment but is sometimes not feasible or even contraindicated.\n                    Additionally, in cases with severe CS, rapid control of hypercortisolism may be\n                    required. In these scenarios, steroidogenesis inhibitors represent a therapeutic\n                    alternative to surgery. Over the last years, the knowledge of the broad\n                    therapeutic effects of steroidogenesis inhibitors per se and the number of\n                    available drugs have increased. However, large comparative studies are still\n                    lacking. Accordingly, the decision on which drug to be used in a certain patient\n                    or clinical setting may be difficult. This review aims to summarize the main\n                    characteristics of steroidogenesis inhibitors.<\/jats:p>","DOI":"10.1055\/a-2317-0801","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T22:56:41Z","timestamp":1714517801000},"page":"723-731","source":"Crossref","is-referenced-by-count":3,"title":["Medical Therapy of Endogenous Cushing\u2019s Syndrome with Steroidogenesis\n                    Inhibitors: Treatment Rationale, Available Drugs, and Therapeutic\n                    Effects"],"prefix":"10.1055","volume":"132","author":[{"given":"Mario","family":"Detomas","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Endocrinology and\n                    Diabetes, University Hospital, University of W\u00fcrzburg, W\u00fcrzburg,\n                    Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timo","family":"Deutschbein","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Endocrinology and\n                    Diabetes, University Hospital, University of W\u00fcrzburg, W\u00fcrzburg,\n                    Germany"},{"name":"Medicover Oldenburg MVZ, Oldenburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Altieri","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine I, Division of Endocrinology and\n                    Diabetes, University Hospital, University of W\u00fcrzburg, W\u00fcrzburg,\n                    Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,6,14]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1001\/jama.2023.11305","article-title":"Cushing syndrome: A review","volume":"330","author":"M Reincke","year":"2023","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/S2213-8587(16)00086-3","article-title":"Complications of Cushing's syndrome: State of the art","volume":"4","author":"R Pivonello","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1007\/s11102-022-01262-8","article-title":"Cushing's disease: Adrenal steroidogenesis inhibitors","volume":"25","author":"R Pivonello","year":"2022","journal-title":"Pituitary"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1060884","DOI":"10.3389\/fendo.2022.1060884","article-title":"Individualized medical treatment options in Cushing disease","volume":"13","author":"A Gilis-Januszewska","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1210\/jc.2013-3628","article-title":"Ketoconazole in Cushing's disease: Is it worth a try?","volume":"99","author":"F Castinetti","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1145775","DOI":"10.3389\/fendo.2023.1145775","article-title":"Ketoconazole as second-line treatment for Cushing's disease after\n                    transsphenoidal surgery: Systematic review and meta-analysis","volume":"14","author":"C Viecceli","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1530\/EJE-17-0886","article-title":"Hepatic safety of ketoconazole in Cushing's syndrome: Results of a\n                    Compassionate Use Programme in France","volume":"178","author":"J Young","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1210\/er.2013-1048","article-title":"The treatment of Cushing's disease","volume":"36","author":"R Pivonello","year":"2015","journal-title":"Endocr Rev"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S2213-8587(19)30313-4","article-title":"Efficacy and safety of levoketoconazole in the treatment of endogenous\n                    Cushing's syndrome (SONICS): A phase 3, multicentre, open-label, single-arm\n                    trial","volume":"7","author":"M Fleseriu","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s11102-022-01263-7","article-title":"Levoketoconazole in the treatment of patients with endogenous Cushing's\n                    syndrome: A double-blind, placebo-controlled, randomized withdrawal study\n                    (LOGICS)","volume":"25","author":"R Pivonello","year":"2022","journal-title":"Pituitary"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"4146","DOI":"10.1210\/jc.2015-2616","article-title":"Effectiveness of metyrapone in treating Cushing's syndrome: A retrospective\n                    multicenter study in 195 patients","volume":"100","author":"E Daniel","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1007\/s12020-018-1675-4","article-title":"Metyrapone treatment in Cushing's syndrome: A real-life study","volume":"62","author":"F Ceccato","year":"2018","journal-title":"Endocrine"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"A515","DOI":"10.1210\/jendso\/bvab048.1053","article-title":"Metyrapone treatment in endogenous Cushing\u2019s syndrome: Results at week 12 from\n                    PROMPT, a prospective international multicenter, open-label, phase III\/IV\n                    study","volume":"5","author":"L K Nieman","year":"2021","journal-title":"J Endocr Soc"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"903545","DOI":"10.3389\/fendo.2022.903545","article-title":"Metyrapone versus osilodrostat in the short-term therapy of endogenous\n                    Cushing's syndrome: Results from a single center cohort study","volume":"13","author":"M Detomas","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S2213-8587(20)30240-0","article-title":"Efficacy and safety of osilodrostat in patients with Cushing's disease\n                    (LINC 3): A multicentre phase III study with a double-blind, randomised\n                    withdrawal phase","volume":"8","author":"R Pivonello","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e2882","DOI":"10.1210\/clinem\/dgac178","article-title":"Randomized trial of osilodrostat for the treatment of Cushing disease","volume":"107","author":"M Gadelha","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1210\/clinem\/dgac691","article-title":"Efficacy and safety of osilodrostat in paraneoplastic Cushing syndrome: A\n                    real-world multicenter study in France","volume":"108","author":"A Dormoy","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"L1","DOI":"10.1093\/ejendo\/lvad167","article-title":"Prolonged adrenal insufficiency following discontinuation of osilodrostat\n                    treatment for intense hypercortisolism","volume":"190","author":"A Ferriere","year":"2024","journal-title":"Eur J Endocrinol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/cen.14551","article-title":"Osilodrostat in Cushing's disease: The risk of delayed adrenal\n                    insufficiency should be carefully monitored","volume":"98","author":"F Castinetti","year":"2023","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"K29","DOI":"10.1093\/ejendo\/lvad060","article-title":"Prolonged adrenocortical blockade following discontinuation of Osilodrostat","volume":"188","author":"J Poirier","year":"2023","journal-title":"Eur J Endocrinol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1530\/EJE-12-0358","article-title":"Efficiency and tolerance of mitotane in Cushing's disease in 76 patients\n                    from a single center","volume":"167","author":"C Baudry","year":"2012","journal-title":"Eur J Endocrinol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/ejendo\/lvae007","article-title":"Recovery of adrenal function after stopping mitotane in patients with\n                    adrenocortical carcinoma","volume":"190","author":"B Altieri","year":"2024","journal-title":"Eur J Endocrinol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"203","DOI":"10.23736\/S2724-6507.21.03601-0","article-title":"Mitotane treatment in adrenocortical carcinoma: Mechanisms of action and\n                    predictive markers of response to therapy","volume":"47","author":"B Altieri","year":"2022","journal-title":"Minerva Endocrinol (Torino)"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"2234","DOI":"10.3390\/cells11142234","article-title":"MicroRNAs and long non-coding RNAs in adrenocortical carcinoma","volume":"11","author":"M Detomas","year":"2022","journal-title":"Cells"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European Society of Endocrinology Clinical Practice Guidelines on the management\n                    of adrenocortical carcinoma in adults, in collaboration with the European\n                    Network for the Study of Adrenal Tumors","volume":"179","author":"M Fassnacht","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1530\/EJE-18-0923","article-title":"Adjuvant mitotane therapy is beneficial in non-metastatic adrenocortical\n                    carcinoma at high risk of recurrence","volume":"180","author":"A Calabrese","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1210\/jc.2009-1317","article-title":"Management of Cushing's syndrome due to ectopic adrenocorticotropin\n                    secretion with 1,ortho-1, para'-dichloro-diphenyl-dichloro-ethane: Findings\n                    in 23 patients from a single center","volume":"95","author":"B Donadille","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3390\/cancers12020359","article-title":"Effects of germline CYP2W1*6 and CYP2B6*6 single nucleotide polymorphisms on\n                    mitotane treatment in adrenocortical carcinoma: A multicenter ENSAT study","volume":"12","author":"B Altieri","year":"2020","journal-title":"Cancers (Basel)"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1530\/endoabs.73.PEP1.7","article-title":"Adverse events of mitotane treatment in patients with adrenocortical\n                    carcinoma","author":"B Altieri","year":"2021","journal-title":"Endocrine Abstracts"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s11102-016-0742-1","article-title":"Updates on the role of adrenal steroidogenesis inhibitors in Cushing's\n                    syndrome: A focus on novel therapies","volume":"19","author":"M Fleseriu","year":"2016","journal-title":"Pituitary"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/20420188211058583","article-title":"Pharmacological management of severe Cushing's syndrome: The role of\n                    etomidate","author":"A Pence","year":"2022","journal-title":"Ther Adv Endocrinol Metab"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1159\/000088587","article-title":"Efficient short-term control of hypercortisolaemia by low-dose etomidate in\n                    severe paediatric Cushing's disease","volume":"64","author":"J E Greening","year":"2005","journal-title":"Horm Res"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.redare.2023.09.001","article-title":"Etomidate in the treatment of Cushing syndrome","volume":"70","author":"N Vergara Molina","year":"2023","journal-title":"Rev Esp Anestesiol Reanim (Engl Ed)"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1210\/jcem-70-5-1426","article-title":"Infusion of low dose etomidate: correction of hypercortisolemia in patients with\n                    Cushing's syndrome and dose-response relationship in normal subjects","volume":"70","author":"H M Schulte","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1097\/CCM.0b013e31822d7938","article-title":"Corticosteroid after etomidate in critically ill patients: A randomized\n                    controlled trial","volume":"40","author":"J F Payen","year":"2012","journal-title":"Crit Care Med"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1210\/jc.2011-0536","article-title":"Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to\n                    rescue adrenalectomy for severe ACTH-dependent Cushing's syndrome","volume":"96","author":"P Kamenicky","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1530\/EJE-14-0913","article-title":"Rapid control of severe neoplastic hypercortisolism with metyrapone and\n                    ketoconazole","volume":"172","author":"J B Corcuff","year":"2015","journal-title":"Eur J Endocrinol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1530\/EDM-21-0071","article-title":"Synergistic cortisol suppression by ketoconazole-osilodrostat combination\n                    therapy","volume":"2021","author":"V Amodru","year":"2021","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"102908","DOI":"10.1016\/j.arcmed.2023.102908","article-title":"Pharmacological treatment of Cushing's syndrome","volume":"54","author":"F Castinetti","year":"2023","journal-title":"Arch Med Res"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1210\/clinem\/dgab122","article-title":"Approach to the patient treated with steroidogenesis inhibitors","volume":"106","author":"F Castinetti","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1258\/acb.2011.011014","article-title":"Comparison of serum cortisol measurement by immunoassay and liquid\n                    chromatography-tandem mass spectrometry in patients receiving the\n                    11beta-hydroxylase inhibitor metyrapone","volume":"48","author":"P J Monaghan","year":"2011","journal-title":"Ann Clin Biochem"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/cen.12259","article-title":"High variability in baseline urinary free cortisol values in patients with\n                    Cushing's disease","volume":"80","author":"S Petersenn","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1530\/EJE-19-0695","article-title":"Use of late-night salivary cortisol to monitor response to medical treatment in\n                    Cushing's disease","volume":"182","author":"J Newell-Price","year":"2020","journal-title":"Eur J Endocrinol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"833644","DOI":"10.3389\/fendo.2022.833644","article-title":"Ketoconazole- and metyrapone-induced reductions on urinary steroid metabolites\n                    alter the urinary free cortisol immunoassay reliability in Cushing syndrome","volume":"13","author":"A Vega-Beyhart","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s40618-023-02128-x","article-title":"Erythropoiesis in Cushing syndrome: Sex-related and subtype-specific\n                    differences. Results from a monocentric study","volume":"47","author":"M Detomas","year":"2024","journal-title":"J Endocrinol Invest"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1530\/EJE-22-0211","article-title":"Subtype-specific pattern of white blood cell differential in endogenous\n                    hypercortisolism","volume":"187","author":"M Detomas","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1530\/endoabs.90.P811","article-title":"Comparison of Metyrapone, OSilodrostat and KEToconazolE in the short-term\n                    thERapy of endogenous Cushing\u2019s syndrome: Preliminary results of the MOSKETEER\n                    study","volume":"90","author":"M Detomas","year":"2023","journal-title":"Endocrine Abstracts"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1530\/EJE-22-0320","article-title":"11-Oxygenated C19 steroids are the predominant androgens responsible for\n                    hyperandrogenemia in Cushing's disease","volume":"187","author":"H F Nowotny","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1530\/EJE-22-0208","article-title":"Differences in the spectrum of steroidogenic enzyme inhibition between\n                    osilodrostat and metyrapone in ACTH-dependent Cushing syndrome patients","volume":"187","author":"F Bonnet-Serrano","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s11102-022-01268-2","article-title":"Treatment of Cushing's syndrome with osilodrostat: Practical applications\n                    of recent studies with case examples","volume":"25","author":"M Fleseriu","year":"2022","journal-title":"Pituitary"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3389\/fendo.2020.00648","article-title":"Medical treatment of Cushing's disease: An overview of the current and\n                    recent clinical trials","volume":"11","author":"R Pivonello","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1210\/en.2015-2052","article-title":"ATR-101, a selective and potent inhibitor of acyl-CoA acyltransferase 1, induces\n                    apoptosis in H295R adrenocortical cells and in the adrenal cortex of dogs","volume":"157","author":"C R LaPensee","year":"2016","journal-title":"Endocrinology"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1002\/jcph.1925","article-title":"A Target-mediated drug disposition model to explain nonlinear pharmacokinetics\n                    of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor SPI-62 in healthy\n                    adults","volume":"61","author":"N Wu","year":"2021","journal-title":"J Clin Pharmacol"}],"container-title":["Experimental and Clinical Endocrinology &amp; Diabetes"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2317-0801.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T23:46:39Z","timestamp":1733960799000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2317-0801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,30]]},"references-count":53,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12,11]]},"published-print":{"date-parts":[[2024,12]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2317-0801","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0947-7349","1439-3646"],"issn-type":[{"value":"0947-7349","type":"print"},{"value":"1439-3646","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,4,30]]},"published":{"date-parts":[[2024,4,30]]}}}